I’ve been watching the numbers for months and something finally clicked. The sheer scale of the announced data-center build-out feels almost unreal. Analysts keep throwing around figures that make earlier infrastructure booms look modest by comparison. If everything goes according to plan, the spending could reach levels never seen before relative to the broader economy. Yet the more I look at those projections, the more I start wondering what happens if the timeline stretches or the demand softens even a little.
Why Cutting Tech Exposure Matters Right Now
Most of us have enjoyed the ride. Hardware makers and the companies that supply them have delivered extraordinary profits while capacity stayed tight. But markets have a way of pricing in perfection. When the first signs of hesitation appear in data-center or memory names, the reaction can be sharp. That is exactly what has been happening in recent weeks. A few missed expectations or delayed orders and the narrative shifts quickly from endless demand to overcapacity concerns.
The bigger issue sits inside emerging-market indexes. Nearly half of the standard emerging-markets benchmark now sits in technology, and most of that is hardware. When you hold a broad emerging-markets ETF, you are carrying more AI-related risk than the label suggests. I used to treat that exposure as an acceptable by-product of global growth. Lately it has started to feel like an unintended concentration.
In my own model portfolio the emerging-markets sleeve had grown to a meaningful weight. Ten percent sat in a broad emerging-markets fund and another five percent in a “true” emerging-markets version that deliberately excludes the biggest Asian technology hubs. That combination looked balanced on paper. In practice it still left a sizable tech footprint that was hard to see at a glance.
The Hidden Tech Weight Inside Emerging Markets
It is easy to forget how much the composition of these indexes has changed. A decade ago emerging markets meant commodities, banks, and consumer names. Today the same indexes lean heavily toward semiconductors, electronics, and the supply chains that feed the artificial-intelligence build-out. Korea and Taiwan alone can dominate the technology portion. Even China, despite its own policy swings, contributes a large hardware footprint.
Reducing the broad emerging-markets allocation from ten percent to five percent does not eliminate the region. It simply makes the technology component more transparent. The remaining five percent stays alongside the dedicated true-emerging-markets holding, so the overall emerging-markets weight remains ten percent. The difference is that the technology risk is now smaller and easier to measure.
I prefer this approach because it keeps the option open. If the AI cycle continues without interruption, nothing stops me from adding an explicit semiconductor fund later. The exposure becomes a conscious choice rather than an accident of index construction. Clarity itself has value when markets turn volatile.
Healthcare as the Quiet Counterweight
When you scan sector performance over the past year, one group stands out for moving in the opposite direction of the technology-heavy indexes. Healthcare has quietly delivered the classic defensive characteristics that many investors have been looking for. It does not mean the sector is risk-free. Political pressure on medical costs never disappears. Patent expirations arrive on schedule. A handful of large companies can dominate the index. One major name alone can account for more than ten percent of the sector weight.
Still, the fundamentals remain attractive in their own right. Demographic trends support steady demand for treatments and services. Earnings tend to be less cyclical than most industrial or consumer groups. Valuation relative to the broader market sits close to the long-term average rather than at an extreme premium. In other words, you are not forced to overpay simply to own a defensive sector.
I have watched other defensive areas struggle. Consumer staples face shifting preferences and thinner pricing power in many categories. Utilities can be sensitive to interest-rate moves. Healthcare, for all its quirks, continues to offer a cleaner combination of growth and resilience. That combination makes it useful when the goal is simply to step away from concentrated technology risk.
Practical Steps for Rebalancing the Portfolio
The actual change is straightforward. Reduce the broad emerging-markets ETF holding by half and redirect the proceeds into a global healthcare ETF. The net effect is a five-percent position in healthcare that sits alongside the remaining emerging-markets exposure. No dramatic overhaul is required. The rest of the portfolio stays untouched.
Some investors will prefer to keep higher technology exposure but want it visible. In that case an explicit global semiconductor ETF can sit alongside the reduced emerging-markets weight. Others will decide the cycle has run far enough and prefer to stay underweight. Both paths become clearer once the hidden technology component is trimmed.
I have found that the hardest part is often psychological. After years of strong technology returns it feels almost unnatural to take money off the table. Yet portfolios that never rebalance tend to drift into concentrations that only become obvious after the fact. A modest five-percent shift is rarely enough to change long-term outcomes on its own, but it restores a degree of balance that had gradually disappeared.
What the Numbers Actually Suggest About Scale
The projected spending on data centers has been described as historic. Relative to the size of the economy the figures exceed the railway expansion of the late nineteenth century. That comparison is useful because it reminds us how rare such waves of capital expenditure really are. Most of them eventually slow. Capacity catches up with demand. Margins compress. The companies that earned extraordinary profits during the tight phase face a different environment.
None of this means the technology is unimportant. Artificial intelligence will continue to reshape industries for years. The question is simply whether every company currently priced for limitless hardware demand will deliver on that expectation. History suggests some will and some will not. Diversifying away from the purest expression of that theme is less about predicting a collapse and more about acknowledging uncertainty.
When expectations are this elevated, the cost of even modest disappointment can be severe.
That observation has guided the decision more than any single data point. Markets can stay irrational longer than expected, yet the asymmetry of outcomes feels less favorable than it did a year ago. Reducing one source of concentration while adding a sector with different drivers simply feels prudent.
Comparing Defensive Options Side by Side
Not every defensive sector behaves the same way. Consumer staples often struggle when input costs rise or when shoppers trade down. Real estate can be sensitive to financing conditions. Healthcare has its own political and regulatory risks, yet the underlying demand is less discretionary. People do not postpone essential treatments the way they postpone a new appliance or a vacation.
| Sector | Demand Driver | Cyclical Sensitivity | Valuation Context |
| Healthcare | Demographics and innovation | Low to moderate | In line with market |
| Consumer Staples | Everyday consumption | Moderate | Often premium |
| Utilities | Regulated returns | Interest-rate sensitive | Varies with yields |
| Technology Hardware | Capital spending cycles | High | Elevated on growth expectations |
Looking at the table, healthcare stands out for combining structural demand with valuations that have not run far ahead of the broader market. That combination is rare when defensive characteristics are most needed.
Keeping the Emerging Markets Allocation Intact
Some readers may wonder why the emerging-markets weight is not reduced further. The answer is simple. Growth outside the developed world still matters. Demographics, rising middle classes, and underpenetrated markets continue to offer opportunities that are hard to find elsewhere. The goal was never to abandon the region. It was to remove the accidental technology overweight that had developed inside the standard indexes.
By keeping a dedicated true-emerging-markets position and a smaller broad emerging-markets holding, the portfolio retains exposure to countries and sectors that are less tied to the current AI infrastructure cycle. That mix feels more intentional than the previous arrangement.
In my experience, investors who try to time complete exits from an entire region often end up missing the next phase of recovery. A measured reduction of one component achieves most of the risk-management goal without forcing a binary decision.
How Concentration Creeps Into Portfolios
Concentration rarely arrives overnight. It builds through strong relative performance. Technology has outperformed for so long that even a modest starting allocation can grow into a large one. Index providers rebalance according to market capitalization, so the winners keep gaining weight. Passive investors inherit that drift whether they notice it or not.
Active monitoring helps, but only if the numbers are examined at a granular level. Looking at the headline emerging-markets percentage is not enough. You need to know how much of that percentage sits in semiconductors, memory, and related hardware. Once that figure becomes large, the portfolio starts to behave more like a technology portfolio than a diversified global one.
The same process can happen inside developed-market indexes, of course. The difference is that most investors already know their large-cap funds are heavy in technology. The emerging-markets side has been less obvious until recently.
Valuation Reality Check for Healthcare
One common objection is that healthcare does not look cheap. On a forward earnings basis the sector trades at roughly the same multiple as the broader developed-market index. That is true. Yet the comparison misses an important point. The broader index itself carries elevated multiples largely because of its technology and growth components. Healthcare is not expensive relative to its own history either.
More importantly, the quality of the earnings stream differs. Predictable cash flows and lower cyclicality often justify a modest premium. When the alternative is a set of hardware companies priced for continued scarcity, the relative valuation starts to look more reasonable.
I do not claim healthcare is a bargain in absolute terms. I simply argue that it offers a better risk-reward balance for the portion of the portfolio that needs to step away from pure technology exposure.
Behavioral Side of Portfolio Changes
Making the switch is only half the battle. Living with it can be harder. If technology continues to surge, the healthcare allocation will lag and the decision will feel premature. That is the nature of diversification. You accept the possibility of underperformance in one scenario in exchange for protection in another.
I have learned to judge these moves by process rather than short-term outcome. Was the concentration real? Was the alternative sector fundamentally sound? Was the size of the change modest enough to avoid large opportunity cost? When the answers are yes, the decision holds even if markets move against it for a while.
Perhaps the most useful mindset is to treat the change as insurance rather than a prediction. Insurance feels expensive when nothing goes wrong. It feels essential when it does.
Looking Beyond the Next Twelve Months
Short-term market noise can distract from longer structural points. Demographics continue to favor healthcare spending across most developed and many emerging economies. Innovation in treatments and medical technology remains rapid. At the same time the capital intensity of the AI infrastructure build-out is so large that even small deviations from plan can produce significant swings in demand for certain components.
Neither theme is likely to disappear in a single year. Positioning for both, rather than leaning entirely into one, feels more consistent with a multi-year investment horizon. The five-percent healthcare addition is small enough that it will not dominate returns, yet large enough to matter if technology experiences a prolonged period of digestion.
- Reduce broad emerging-markets technology concentration
- Maintain overall emerging-markets regional exposure
- Add a sector with different demand drivers
- Keep the option to increase explicit technology exposure later
- Improve transparency of portfolio risk factors
Those five points summarize the logic behind the change. None of them requires a dramatic forecast about the end of the AI cycle. They simply acknowledge that concentration has increased and that a modest rebalancing restores better balance.
Common Questions Investors Ask
Will this move hurt performance if AI spending stays strong? Possibly in the short run. Over longer periods the difference should be modest because the position size is limited. Is healthcare the only defensive option? No, but it currently offers a cleaner combination of fundamentals and valuation than most alternatives. Should the reduction in emerging markets go further? Only if an investor has a strong negative view on the region as a whole. Most do not.
Another frequent question concerns the timing. Why now rather than a year ago or a year from now? The answer is that concentration has become more visible and market pricing has grown more optimistic. Acting when both conditions are present is usually better than waiting for a clear signal that may never arrive in time.
Building a Habit of Regular Review
One change does not solve portfolio management forever. Markets evolve and indexes change composition. The useful habit is to examine every major holding for unintended factor exposures at least once a year. Technology weight inside emerging markets was not an issue five years ago. It is an issue today. Other concentrations will appear in the future.
I keep a simple checklist: what is the largest sector weight inside each regional or style fund? How has that weight changed over the past two years? Does the current level still match the original intention of the holding? When the answers drift, a small adjustment is usually enough to restore alignment.
That process feels less like market timing and more like basic housekeeping. Portfolios that receive regular attention tend to stay closer to the risk profile their owners actually want.
Final Thoughts on Measured Diversification
The AI infrastructure story remains powerful. Enormous sums are being committed and the underlying technology continues to advance. At the same time, the scale of the projections leaves little room for error. When nearly half of an emerging-markets index sits in related stocks, the risk becomes harder to ignore.
Moving five percent from a broad emerging-markets fund into a global healthcare fund does not reject the technology theme. It simply refuses to let that theme dominate every corner of the portfolio. The emerging-markets exposure stays intact at the regional level. The technology component becomes more transparent. A sector with different drivers gains a seat at the table.
In my view that combination improves the overall balance without requiring extreme forecasts. Markets will decide the short-term outcome. The process of identifying concentration and addressing it deliberately remains useful regardless of what happens next. Investors who keep that habit tend to sleep better when the narrative eventually shifts, as it almost always does.
The change is small. The principle behind it is not. Clear risk, intentional allocation, and a willingness to adjust when concentrations appear are the foundations of durable portfolio construction. Everything else is noise.
